It has been proven that CTC enumeration represents an independent prognostic indicator, and correlates with the survival and potential for relapse in patients with breast, prostate and colorectal cancer. The CTC test, which is distributed by Veridex LLC (a Johnson & Johnson Company), is able to identify, visualize, and count CTC in a small (7.5 ml) blood sample to predict disease progression and survival. Through the ability to locate as low as one CTC among 40 billion cells in the blood sample – an achievement no other diagnostic approach has been able to accomplish – the CTC test can assist oncologists to make timely, informed decisions about patient care. Further, it is the only diagnostic platform which has been approved by the U.S. Federal Drug Administration as unique resource critical for patient management in metastatic cancers of the breast, prostate, and colon, and their monitoring. In these cancer types, it has been proven that CTC act as independent prognostic indicator of patient free and overall survival (see figures below).